In their second antibody drug conjugate (ADC) partnership together, AstraZeneca has agreed to collaborate with Daiichi Sankyo to develop and commercialise its Phase I candidate DS-1062 for the treatment of solid tumours connected to the TROP2 gene, such as non-small cell lung cancer. The deal comes just over a year after the two companies agreed to develop trastuzumab deruxtecan (now known as Enhertu®), which gained US approval in December 2019 for previously treated HER2-positive breast cancer.